Would you like your treatment center to become part of the referral system for MDS patients and be designated as a Center of Excellence? To be recognized as a Center of Excellence, an institution must have:
An established university (or equivalent) program
Recognized morphologic expertise in MDS
Available cytogenetics and/or molecular genetics
Ongoing research, including Institutional Review Board-approved clinical trials
Documentation of peer-reviewed publications in the field
Clinical trials study new interventions (drugs or procedures) to evaluate their safety and effectiveness in humans. Trials follow a careful set of steps, allowing for the systematic gathering of information to answer questions and confirm hypotheses that were formed earlier, in either laboratory experiments or preliminary trials.
If you are an MDS patient, you may wish to discuss a trial with your primary treating physician to see if you qualify as a candidate. LEARN MORE
Onconova is evaluating oral rigosertib in combination with azacitidine in a Phase 2 trial for patients with 1st-line MDS/AML.
Phase 2 09-08 Trial (NCT01926587)
A Phase 1/2 study of the combined administration of oral rigosertib with azacitidine in patients with myelodyspla
The Pivotal MDS Trial INSPIRE is Now Recruiting Patients
INternational Study of Phase III Intravenous RigosErtib
A Phase III, international, randomized, controlled study of Rigosertib +